Applying to the Consultation-Liaison Psychiatry Program

Applying to the Consultation-Liaison Psychiatry Fellowship

Our Consultation-Liaison Psychiatry Fellowship program at UMass Chan-Baystate is actively recruiting applicants from diverse backgrounds, including those who are traditionally underrepresented in medicine. We seek applicants with diversity in religion, race, ethnicity, gender, background, and orientation to reflect the patient population we serve.

Baystate Health is committed to creating an environment that is inclusive of all people.

How to Apply

For the 2024-2025 fellowship application year, the UMass Chan Medical School-Baystate CL Psychiatry Fellowship is excited to announce that we are accepting applications either through the ERAS website, or directly via email using the ACLP Common Application. All applications will be reviewed and considered equally regardless of how the application is submitted. Our goal is to make the application process as inclusive and smooth as possible for everyone.


For more information on Consultation-Liaison Psychiatry fellowships, please visit ACLP's website: Information for Psychiatry Residents.

For further information on ERAS and submission timelines, please review the following website: ERAS Fellowship Timeline

In order to obtain your ERAS token: ERAS Token

For applicants submitting by email, the ACLP common application can be found here: ACLP Fellowship Common Application

Interested applicants should contact the Program Director and Program Coordinator for additional application information. Completed applications, including letters of recommendation, are due no later than October 31 for fellowship positions beginning the following academic year. Applicants are invited to virtual interviews from September to late November, and positions are offered through the NRMP Match process.

To submit the completed ACLP Common Application and supporting materials, please email the Program Director and Program Coordinator: Flannery Merideth, MD and Martany Aguirre.

We look forward to hearing from you!

Back to Top